Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 6th, 2023
1:00 PM - 4:30 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Pat DeMartino, MD; Douglas Carr, MD; Cat Livingston, MD; Caryn Mickelson, PharmD; Robin Moody, MPH; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Deborah Weston, JD; Kyle Hamilton; Trevor Douglass, DC, MPH; Jennifer Bowen; Melissa Yokoyama, PharmD

Audience: Rushi Parikh, Provention Bio*; Jason Kniffin, Novo Nordisk; Mark Kantor, AllCare Health; Sandee Merrick, Provention Bio; Bill Gittinger, MTPA; Brandie Feger, Advanced Health CCO; Chris Ferrin, Samaritan Health Plans; Gary Parenteau, Dexcom Inc; Lori McDermott, Viking HCS; Mark Wolber, Sunovion; Matt Worthy, OHSU; Melissa Abbott, Eisai; Stuart O'Brochta, Gilead; Nirmal Ghuman; Norman Navarro, Providence; Rushi Paikh, Provention Bio; Saghi Maleki, Takeda Pharmaceuticals; Shauna Wick; Stuart O'Brochta, Gilead; Sydney Wardan, UHA; Erin Nowak, AbbVie; Tiina Andrews, UHA; YJ Shukla, Moda Health EOCCO; Baltazar Diaz, Pacificsource; Melanie Greer, Legacy; Linda Finch, Biogen

(*) Provided verbal testimony

I. CALL TO ORDER

A. Roll Call & Introductions
- Called to order at approx. 1:05 p.m., introductions by Committee and staff

B. Conflict of Interest Declaration – no new conflicts of interest were declared

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

C. Approval of Agenda and February 2023 Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor with one abstention

D. Department Update provided by Andrew Gibler, PharmD

E. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization (PA) Updates
Recommendation:
- Add: Orserdu™ (elacestrant); Lunsumio™ (mosunetuzumab-axgb); Adstiladrin® (nadofaragene firadenovec-vncg) and Jaypirca™ (pirtobrutinib) to Table 1 in the Oncology Agents prior authorization (PA) criteria

B. Glaucoma Drugs Class Update & New Drug Evaluation (NDE)
Recommendation:
- No PDL changes recommended based on review of recently published evidence
- Maintain omidenepag as non-preferred on the PDL
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

III. DUR NEW BUSINESS

A. Generalized Anxiety Disorder (GAD) Update and Pregabalin Drug Use Evaluation: Andrew Gibler, PharmD and Sarah Servid, PharmD
Recommendations:
- Make pregabalin IR capsules preferred
- Update Pregabalin PA criteria to: include GAD; remove gabapentin step therapy for all conditions; and suggest trial of a preferred gabapentinoid product
- Align coverage criteria by removing PA for preferred pregabalin

ACTION: The Committee recommended deferring the topic and asked staff to bring back evidence for safety and efficacy of pregabalin in GAD, and both gabapentin and pregabalin for other diagnoses for Committee to consider before opening coverage
Motion to defer, 2nd, 8 in-favor with one opposed

B. Non-preferred Drugs in Select PDL Classes PA Update: Dave Engen, PharmD
Recommendations:
- Update Non-Preferred Drugs PA criteria to allow approval durations of up to 12 months for patients with a previously approved PA

ACTION: Motion to approve, 2nd, all in favor

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

C. GLP-1 Receptor Agonists for Diabetes Policy Evaluation: Melissa Yokoyama, PharmD
Recommendations:
- Maintain current PA policy
ACTION: Motion to approve, 2nd, all in favor

IV. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Tzield™ (teplizumab-mzwv) NDE: Kathy Sentena, PharmD
Recommendations:
- Include with Miscellaneous Antidiabetic Agents class on the PDL and designate as non-preferred
- Implement proposed PA criteria to limit use to people with stage 2 T1DM and high risk of progression to stage 3 T1DM
ACTION: The Committee amended the proposed criteria to add question #4 to deny coverage to those patients who have already progressed to stage 3 T1DM diagnosis; amend question #7 (previously #6) to include dysglycemia as defined by FPG, OGTT, 2-h plasma glucose or HbA1c; and remove the requirement that improvement be documented within one month of the renewal request
Motion to approve, 2nd, all in favor

B. Growth Hormone Focused Class Update for Adults: Dave Engen, PharmD
Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Update PA criteria as proposed
- Evaluate costs in executive session
ACTION: Motion to approve, 2nd, all in favor

C. Circadian Rhythm Sleep-Wake Disorders Indication Review: Sarah Servid, PharmD
Recommendations:
- Continue to require PA to limit use to FDA-labeled and funded indications and update criterion as proposed
- If medically necessary for funded circadian rhythm sleep-wake disorders or if covered under EPSDT, require trial of a melatonin agonist or melatonin before approving sedating drugs and make at least one melatonin agonist preferred
- Evaluate costs in executive session
ACTION: Motion to approve, 2nd, all in favor

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

D. Amyotrophic Lateral Sclerosis Class Update & NDE: Sara Fletcher, PharmD
Recommendations:
- Designate riluzole as preferred and edaravone and sodium phenylbutyrate-taurursodiol as non-preferred on the PDL
- Implement PA criteria for sodium phenylbutyrate-taurursodiol and update edaravone PA criteria as proposed
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Pat DeMartino, MD; Douglas Carr, MD; Cat Livingston, MD; Caryn Mickelson, PharmD; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD

Staff Present: Sara Fletcher, PharmD; Sarah Servid, PharmD; David Engen, PharmD; Deanna Moretz, PharmD; Roger Citron, RPh; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Andrew Gibler, PharmD; Kyle Hamilton

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. Glaucoma Drugs Class Update & NDE
Recommendation: Make brimonidine tartrate 0.1% ophthalmic drops preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

B. Growth Hormone Focused Class Update for Adults
Recommendations: Make no changes to the PDL
ACTION: Motion to approve, 2nd, all in favor

C. Circadian Rhythm Sleep-Wake Disorders Indication Review
Recommendations: Make ramelteon tablets preferred with PA
ACTION: Motion to approve, 2nd, all in favor

D. Amyotrophic Lateral Sclerosis Class Update &NDE
Recommendations: Make riluzole tablets preferred and riluzole film and suspension non-preferred
ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN